MarginsXMarginsX
Home › Markets › Health Care › IMMP

Immutep Limited (IMMP)

IMMP trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$3.40
-2.30% on the day
Market cap
$25.1M
Nano cap
Revenue · 2026
$16.4M
+133.9% on 2025
Net income · 2026
-$53.8M
-328.1% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC filing XBRL, 20-F (ifrs-full:Revenue), fiscal year ended 2026-06-30, https://www.sec.gov/Archives/edgar/data/1506184/000119312526429413/0001193125-26-429413-index.htm. Net income: SEC 20-F (ifrs-full:ProfitLossAttributableToOwnersOfParent), fiscal year ended 2026-06-30. Converted from AUD at 1.4738 per USD (today's ECB or Federal Reserve reference rate).

Profile

FieldValue
TickerIMMP on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryAustralia
IPO yearNot reported by the screener
SEC CIK0001506184
SEC industry codePharmaceutical Preparations
Incorporated inAustralia

Financials · 2026

LineValue
Revenue$16.4M
Net income-$53.8M
Operating incomeNot in SEC XBRL data
Net margin-328.1%
Operating marginOperating income not reported
Revenue growth+133.9%
Cash$43.2M
Total assets$56.5M
P/E (computed)Net income was not positive
P/S (computed)1.5×

Reported in AUD; shown in US dollars.

Warning signs

Cash runway
13.8 months
63.7M AUD cash at June 30, 2026
Share count, 1 year
+1918.3%
2025-06-30 to 2026-06-30 · +2382.5% over 3 years
Going-concern doubt
No
20-F filed October 23, 2026
Insider net buying, 12 months
$0
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.20-F 2026-10-23
Cash and burn63.7M AUD cash; operating cash flow -13.9M AUD a quarter.Report 2026-06-30
Shares outstanding7,368,607 (2026-06-30); 7,301,948 a year earlier; 5,936,531 three years earlier. 1y figure adjusted for splits (1-for-20 overall); 3y figure adjusted for splits (1-for-20 overall).Cover page 2026-06-30
Reverse splits, 3 years1; latest 1-for-20 on 2026-09-28Source 2026-09-28
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorPricewaterhouseCoopers, Sydney, AustraliaPCAOB Form AP 2026-11-05
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Annual results

Fiscal yearRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
FY 2026
2026-06-30
24.2M AUD-79.3M AUD-55.5M AUD63.7M AUDNo debt tags24.2M AUD20-F 2026-10-23
FY 2025
2025-06-30
10.3M AUD-61.4M AUD-62.0M AUD67.4M AUDNo debt tags10.3M AUD20-F 2025-10-24
FY 2024
2024-06-30
7.8M AUD-42.7M AUD-34.8M AUD161.8M AUDNo debt tags7.8M AUD20-F 2025-10-24
FY 2023
2023-06-30
5.2M AUD-39.9M AUD-35.4M AUD123.4M AUDNo debt tags5.2M AUD20-F 2025-10-24
FY 2022
2022-06-30
6.8M AUD-32.2M AUD-30.2M AUD80.0M AUDNo debt tags6.8M AUD20-F 2024-10-22
FY 2021
2021-06-30
4.0M AUD-29.9M AUD-17.6M AUD60.6M AUDNo debt tags4.0M AUD20-F 2023-10-24
FY 2020
2020-06-30
16.5M AUD-13.5M AUD-10.8M AUD26.3M AUDNo debt tags16.5M AUD20-F 2022-10-31
FY 2019
2019-06-30
7.5M AUD-18.3M AUD-15.3M AUD16.6M AUDNo debt tags7.5M AUD20-F 2021-10-25

From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months). Amounts in AUD.

Key SEC documents

DocumentFormFiled
Latest prospectus or offering documentF-32023-04-28
Latest annual report20-F2026-10-23
Latest quarterly / interim6-K2026-11-10

Source: SEC EDGAR submissions feed, 740 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+4.2%
1 month-2.5%
3 months-56.5%
Year to date+21.7%
1 year+89.1%
From 52-week high-94.5%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
CRVOCervoMed Inc.$1.67-1.18%$25.3M
ABVCABVC BioPharma Inc.$0.9400+3.30%$25.4M
EDSAEdesa Biotech Inc. Common Shares$1.89-2.58%$25.5M
LITSLite Strategy Inc.$0.8565+1.16%$25.6M
ACETAdicet Bio Inc.$2.75-1.08%$25.7M
IXHLIncannex Healthcare Inc.$1.93-2.03%$24.2M
BYSIBeyondSpring Inc.$0.5788-3.73%$23.8M
MIRAMIRA Pharmaceuticals Inc.$0.6310-4.38%$26.5M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier